The Securities and Exchange Commission has not necessarily reviewed the information in this filing and has not determined if it is accurate and complete. | |||||||||||||||||||||
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 13F FORM 13F INFORMATION TABLE |
|
COLUMN 1 | COLUMN 2 | COLUMN 3 | COLUMN 4 | COLUMN 5 | COLUMN 6 | COLUMN 7 | COLUMN 8 | ||||
VALUE | SHRS OR | SH/ | PUT/ | INVESTMENT | OTHER | VOTING AUTHORITY | |||||
NAME OF ISSUER | TITLE OF CLASS | CUSIP | (x$1000) | PRN AMT | PRN | CALL | DISCRETION | MANAGER | SOLE | SHARED | NONE |
Akero Therapeutics, Inc | COM | 00973Y108 | 89,973 | 3,954,858 | SH | DFND | 3,954,858 | 0 | 0 | ||
Apellis Pharmaceuticals, Inc | COM | 037530106 | 24,090 | 1,000,000 | SH | DFND | 1,000,000 | 0 | 0 | ||
Menlo Therapeutics Inc. | COM | 586858102 | 6,548 | 1,461,552 | SH | DFND | 1,461,552 | 0 | 0 | ||
Precision Biosciences Inc. | COM | 74019P108 | 35,785 | 4,265,141 | SH | DFND | 4,265,141 | 0 | 0 | ||
Turning Point Therapeutics Inc. | COM | 90041T108 | 50,394 | 1,340,265 | SH | DFND | 1,340,265 | 0 | 0 | ||
Verona Pharma PLC | SPONSORED ADS | 925050106 | 3,999 | 875,000 | SH | DFND | 875,000 | 0 | 0 |